Merger Arbitrage Specialist Glick discusses understanding Horizon Therapeutics and Seagen portfolio and cross-market effects with a drug pricing specialist on an Analyst/Industry conference call to be held on April 19 at 11 am. Webcast Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HZNP:
- Viridian Therapeutics initiated with an Overweight at Wells Fargo
- Horizon Therapeutics announces FDA approval of Tepezza indication update
- Horizon announces results from Tepezza trial in patients with CAS, TED
- Viridian Therapeutics initiated with a Buy at Stifel
- Horizon Therapeutics presents MRI imaging data from Phase 3 trial of UPLIZNA
